A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
ACADEMIA
Drug-Use Result Surveys Should Be Conducted in Elaborate Manner: Dr Narukawa
Surveys conducted by companies during the reexamination period should be more elaborately designed, Mamoru Narukawa, associate professor at Kitasato University School of Pharmacy, said in a recent interview with Jiho. Dr Narukawa expressed concerns about drug-use result surveys and all-case…
To read the full story
ACADEMIA
- Japan Medical Societies Release Tavneos Discontinuation Guidance
November 6, 2026
- Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
- Early Pregnancy DOAC Exposure Not Linked to Higher Birth Defect Risk: Study
October 30, 2026
- First iPS Heart Sheet Patient Recovering Well, Set for Discharge
October 22, 2026
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…